A multinational company of american origin announced Tuesday the selection of a vaccine candidate for COVID-19that might be available for authorization of emergency use at the beginning of 2021.
In a statement, the company Johnson and Johnson noted that it expects to initiate phase one of the human clinical studies of the vaccine in September 2020; while anticipating that the data on safety and efficacy are available at the end of the year.
The above may allow the first batches to be available at the beginning of 2021.
“A period considerably accelerated in comparison with the typical process of development of vaccines”, which covers five to seven years.
The vaccine is the product of a partnership with the Department of Health and Human Services united States.
“Together they have committed more than a billion dollars in investment to finance the research, development and clinical testing of vaccines”, he said.